KR20130019725A - A pharmaceutical composition comprising the fractions of water extract from curcuma longa l. for preventing alcoholic liver damage - Google Patents
A pharmaceutical composition comprising the fractions of water extract from curcuma longa l. for preventing alcoholic liver damage Download PDFInfo
- Publication number
- KR20130019725A KR20130019725A KR1020110081853A KR20110081853A KR20130019725A KR 20130019725 A KR20130019725 A KR 20130019725A KR 1020110081853 A KR1020110081853 A KR 1020110081853A KR 20110081853 A KR20110081853 A KR 20110081853A KR 20130019725 A KR20130019725 A KR 20130019725A
- Authority
- KR
- South Korea
- Prior art keywords
- fraction
- water extract
- turmeric
- alcoholic
- chloroform
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 239000000284 extract Substances 0.000 title claims abstract description 66
- 244000163122 Curcuma domestica Species 0.000 title claims abstract description 63
- 208000022309 Alcoholic Liver disease Diseases 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 206010067125 Liver injury Diseases 0.000 claims abstract description 9
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims abstract description 6
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims abstract description 5
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims abstract description 5
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims abstract description 5
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims abstract description 5
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims abstract description 5
- 208000002353 alcoholic hepatitis Diseases 0.000 claims abstract description 5
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 5
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 53
- 235000003373 curcuma longa Nutrition 0.000 claims description 53
- 235000013976 turmeric Nutrition 0.000 claims description 53
- 239000002036 chloroform fraction Substances 0.000 claims description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- 238000000605 extraction Methods 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 9
- 238000005194 fractionation Methods 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 231100000753 hepatic injury Toxicity 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims 1
- -1 lipid peroxide Chemical class 0.000 abstract description 14
- 235000013376 functional food Nutrition 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 8
- 230000001476 alcoholic effect Effects 0.000 abstract description 6
- 231100000234 hepatic damage Toxicity 0.000 abstract description 4
- 230000008818 liver damage Effects 0.000 abstract description 4
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 59
- 230000000694 effects Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 230000003833 cell viability Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 239000002038 ethyl acetate fraction Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 101150081871 CYP2E1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 229930153442 Curcuminoid Natural products 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N demethoxycurcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 울금 물 추출물의 분획물을 유효성분으로 포함하는 알코올성 간 손상 예방용 약학적 조성물에 관한 것으로, 보다 상세하게는 본 발명의 울금의 물 추출물에 대한 클로로포름 또는 에틸아세테이트 분획물을 유효성분으로 포함하는 알코올성 간 손상 예방용 약학적 조성물에 관한 것이다.
The present invention relates to a pharmaceutical composition for preventing alcoholic liver damage comprising a fraction of turmeric water extract as an active ingredient, and more particularly, to a chloroform or ethyl acetate fraction of the turmeric water extract of the present invention as an active ingredient. It relates to a pharmaceutical composition for preventing alcoholic liver injury.
울금(Curcuma Longa L.)은 고온다습한 남부아시아, 아프리카 및 중남미에서 자생하는, 생강과(Zinigiberaceae)에 속하는 다년초 초본식물로서, 우리나라에서는 을금(乙金), 걸금(乞金), 옥금(玉金), 왕금(王金), 심황(深黃)이라고도 부르며, 북부의 산악지대를 제외한 각지에서 재배되고 있다. 울금의 주성분은 커큐미노이드(curcuminoid)이며, 이 중에서 커큐민(curcumin)이 가장 많이 함유되어 있고, 그 외에 p-하이드록시시나모일페룰로일메탄(p-hydroxycinnamoylferuloylmethane) 및 p, p'-다이하이드록시다이시나모일메탄(p, p'-dihydroxydicinnamoylmethane)으로 된 황색색소가 함유되어 있다. 현재까지 보고된 울금의 약리효과로는 위액 분비 촉진, 이뇨 작용, 항암 작용등이 있으며, 울금에 함유된 커큐민은 항균, 항종양, 항아밀로이드와 항염증 작용이 있다고 알려져 있다. Curcuma Longa L. is a perennial herbaceous plant belonging to the Zinigiberaceae, which grows in hot and humid southern Asia, Africa, and Latin America. In Korea, Eulgeum, Gumgeum, and Geumum (玉) It is also called 金, 金 金, and turmeric, and is cultivated in all parts of the country except the mountainous region of the north. The main component of turmeric is curcuminoid, which contains the highest amount of curcumin, and p-hydroxycinnamoylferuloylmethane and p, p'-dihydride. It contains a yellow pigment of p'-dihydroxydicinnamoylmethane. The pharmacological effects of turmeric reported to date include gastric juice secretion, diuretic and anticancer effects. Curcumin contained in turmeric is known to have antimicrobial, anti-tumor, anti-amyloid and anti-inflammatory effects.
한편, 간은 우리 몸에서 각종 대사 작용, 해독, 분해, 합성 및 분비를 담당하는 매우 중요한 장기로서 그 기능을 자세히 살펴보면 다음과 같다. 첫째, 간은 에너지 대사를 관리하는 기능이 있어 음식물에서 흡수된 모든 영양소들을 에너지를 생산할 수 있는 물질로 대사시켜 전신에 공급하거나 저장한다. 둘째, 간은 약 2,000여종의 효소, 알부민, 응고인자들의 혈청단백, 담즙산, 인지질, 콜레스테롤 등의 지방을 합성하고 저장하며 분배하는 기능이 있다. 셋째, 간은 각종 대사산물을 담관을 통해 십이지장으로 배설하는 기능이 있으며, 면역기능이 있어서 우리의 생명유지에 중요한 역할을 한다. 마지막으로, 간은 해독 및 분해 기능이 있어 약물, 독성물질, 술 등을 해독시킨다. 하지만 이러한 간의 해독기능은 간세포를 손상시키기 쉬워 약물성, 독성, 알코올성 간질환 등을 유발시킬 수 있다.Meanwhile, the liver is a very important organ that is responsible for various metabolism, detoxification, decomposition, synthesis and secretion in our body. First, the liver has the ability to manage energy metabolism, which metabolizes all the nutrients absorbed by food into energy-producing substances that are supplied or stored throughout the body. Second, the liver has the function of synthesizing, storing and distributing fats such as serum proteins, bile acids, phospholipids and cholesterol of about 2,000 enzymes, albumin and coagulation factors. Third, the liver has the ability to excrete various metabolites into the duodenum through the bile ducts, and the immune function plays an important role in maintaining our lives. Finally, the liver detoxifies and breaks down drugs, toxicants, and alcohol. However, the liver detoxification function is easy to damage liver cells can cause drug, toxic, alcoholic liver diseases.
알코올성 간 질환은 임상증상에 따라 알코올성 지방간, 알코올성 간염, 알코올성 간경변증으로 크게 나눌 수 있고 대개 하루 60-80 g의 알코올을 10년 정도 마실 때 발생한다. 알코올성 지방간은 과다한 알코올 섭취로 인해 간세포 안에 콜레스테롤과 중성지방이 축적되어 발생하는 것으로 금주만 하게 되면 곧 회복할 수 있으나, 계속 음주하게 되면 간염으로 발전하게 된다. 알코올성 간염은 간세포의 괴사와 염증이 발생한 상태로, 피로감, 식욕부진, 체중감소, 황달, 발열, 우상복부통증 등의 다양한 증상을 보이며, 이를 앓는 환자 중 약 40%는 알코올성 간경변증으로 발전하게 된다. 알코올성 간경변증은 정상 간으로 회복이 불가능한 상태로, 전신 피로감, 식욕 감퇴, 복수, 식도정맥류, 출혈, 간성뇌증, 혼수 등의 다양한 증상을 보이며, 간염 바이러스에 의한 간경변증보다 예후가 불량하여 구미(歐美)에서는 말기 간질환으로 인한 사망의 50%가 알코올에 의한 것으로 알려져 있다.Alcoholic liver disease can be divided into alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis according to clinical symptoms, and it usually occurs when people drink 60-80g of alcohol a day for 10 years. Alcoholic fatty liver is caused by the accumulation of cholesterol and triglycerides in the liver cells due to excessive alcohol intake, which can be recovered soon after drinking, but will continue to develop hepatitis if continued drinking. Alcoholic hepatitis is a condition of necrosis and inflammation of hepatocytes, and shows various symptoms such as fatigue, anorexia, weight loss, jaundice, fever, and right upper abdominal pain, and about 40% of patients with alcoholic liver cirrhosis develop. Alcoholic cirrhosis is a condition that is impossible to recover from normal liver, with various symptoms such as systemic fatigue, loss of appetite, ascites, esophageal varices, bleeding, hepatic encephalopathy, lethargy, and poor prognosis than cirrhosis caused by hepatitis virus. In Esau, 50% of deaths from end-stage liver disease are known to be caused by alcohol.
상기와 같은 알코올성 간 질환 사망률을 줄이기 위하여, 알코올성 간 손상 예방 및 치료제의 개발이 시급한 상황이나, 현재까지 알코올성 간 손상을 치료하기 위한 적절한 치료제, 건강기능식품 및 관련 조성물이 개발되어 있지 않은 실정이다.
In order to reduce the alcoholic liver disease mortality as described above, there is an urgent need to develop alcoholic liver injury prevention and treatment, but until now, no appropriate therapeutic agent, health functional food, and related composition for treating alcoholic liver injury have been developed.
본 발명의 목적은 울금 물 추출물의 분획물을 유효성분으로 함유하는 알코올성 간 손상 예방용 약학적 조성물 및 건강기능식품을 제공하는 것이다.
An object of the present invention is to provide a pharmaceutical composition and health functional food for preventing alcoholic liver damage containing a fraction of turmeric water extract as an active ingredient.
상기의 목적을 달성하기 위하여, 본 발명의 일 측면은 울금 물 추출물의 분획물을 유효성분으로 함유하는 알코올성 간 손상 예방용 약학적 조성물을 제공한다.In order to achieve the above object, one aspect of the present invention provides a pharmaceutical composition for preventing alcoholic liver damage containing a fraction of turmeric water extract as an active ingredient.
또한, 상기 목적을 달성하기 위하여 본 발명 다른 측면은 울금 물 추출물의 분획물을 유효성분으로 함유하는 알코올성 간 손상 예방용 건강기능식품을 제공한다.
In addition, another aspect of the present invention to achieve the above object provides a dietary supplement for preventing alcoholic liver damage containing a fraction of turmeric water extract as an active ingredient.
본 발명의 울금 물 추출물의 분획물은 알코올에 의한 간세포의 손상을 억제하고, 알코올성 지질과산화물의 생성을 억제하며, 항산화 활성을 증가시키는 효과가 있는 바, 알코올성 간 손상의 예방을 위한 의약품 또는 건강기능식품으로서 유용하게 이용될 수 있다.Fractions of turmeric water extract of the present invention inhibits the damage of liver cells by alcohol, inhibits the production of alcoholic lipid peroxides, and increases the antioxidant activity, the drug or health functional food for the prevention of alcoholic liver damage It can be usefully used as.
다만, 본 발명의 효과들은 상기에서 언급한 효과로 제한되지 아니하며, 언급되지 아니한 또 다른 효과들은 하기의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.
However, the effects of the present invention are not limited to the above-mentioned effects, and other effects not mentioned will be clearly understood by those skilled in the art from the following description.
도 1은 HepG2/2E1 세포에서 울금 물 추출물의 알코올에 의한 간세포 손상 예방 효과를 확인한 실험 결과를 나타낸 그림이다.
도 2는 수컷 C57BL/6 마우스에서 울금 물 추출물의 알코올에 의한 ALT 활성 상승 억제 효과를 확인한 실험 결과를 나타낸 그림이다.
도 3은 HepG2/2E1 세포에서 울금 물 추출물, 클로로포름 분획물 및 에틸아세테이트의 알코올에 의한 간손상 예방 효과를 비교한 실험 결과를 나타낸 그림이다.
도 4는 HepG2/2E1 세포에서 울금 물 추출물의 클로로포름 및 에틸아세테이트 분획물의 알코올에 의한 간세포 손상 예방 효과를 확인한 실험 결과를 나타낸 그림이다.
도 5는 HepG2/2E1 세포에서 울금 물 추출물의 클로로포름 분획물의 알코올에 의한 지질과산화물 축적 억제 효과를 확인한 실험 결과를 나타낸 그림이다.
도 6은 울금 물 추출물의 클로로포름 분획물의 항산화 활성을 확인한 실험 결과를 나타낸 그림이다.Figure 1 is a diagram showing the results of experiments confirming the effect of hepatic cell damage caused by alcohol of turmeric water extract in HepG2 / 2E1 cells.
2 is a graph showing the results of experiments confirming the inhibitory effect of alcohol on the ALT activity of turmeric water extract in male C57BL / 6 mice.
Figure 3 is a graph showing the results of experiments comparing the effect of liver water damage by turmeric water extract, chloroform fraction and ethyl acetate in HepG2 / 2E1 cells.
Figure 4 is a diagram showing the results of experiments confirming the effect of preventing chloroform and ethyl acetate fraction of the liver water damage caused by alcohol of turmeric water extract in HepG2 / 2E1 cells.
5 is a graph showing the experimental results confirming the inhibitory effect of lipid peroxide accumulation by alcohol of the chloroform fraction of turmeric water extract in HepG2 / 2E1 cells.
6 is a graph showing the results of experiments confirming the antioxidant activity of the chloroform fraction of turmeric water extract.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 울금(Curcuma Longa L.) 물 추출물의 분획물을 유효성분으로 함유하는 알코올성 간 손상 예방용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing alcoholic liver damage, which contains a fraction of Curcuma Longa L. water extract as an active ingredient.
또한, 본 발명은 울금(Curcuma Longa L.) 물 추출물의 분획물을 유효성분으로 함유하는 알코올성 간 손상 예방용 건강기능식품을 제공한다.In addition, the present invention provides a functional food for preventing alcoholic liver damage containing a fraction of Curcuma Longa L. water extract as an active ingredient.
상기 조성물 또는 건강기능식품에 있어서, 알코올성 간 손상은 알코올성 지방간, 알코올성 간염 또는 알코올성 간경변증인 것이 바람직하나, 이에 한정되지 아니한다.In the composition or dietary supplement, alcoholic liver damage is preferably alcoholic fatty liver, alcoholic hepatitis or alcoholic cirrhosis, but is not limited thereto.
상기 조성물 또는 건강기능식품에 있어서, 분획물은 울금을 열수 추출한 후, 클로로포름으로 분획하여 제조될 수 있고, 클로로포름 분획물을 분리하고 남은 용액을 에틸아세테이트로 다시 분획하여 제조될 수 있다. 더욱 상세하게, 상기 분획물은 1) 반건조시킨 울금을 총 중량의 5 내지 20배의 추출 용매에 침지시키고, 50℃ 내지 250℃의 온도에서 1시간 내지 12시간 동안 추출하는 단계; 2) 상기 단계 1)의 추출물을 여과하는 단계; 및 3)상기 단계 2)의 여과된 추출물을 1 내지 3배 부피의 클로로포름으로 분획하는 단계;를 포함하는 분획 방법에 의하여 제조되는 것이 바람직하나, 이에 한정되지 아니한다.In the composition or health functional food, the fraction may be prepared by hot water extraction of turmeric, fractionated with chloroform, the chloroform fraction is separated and the remaining solution may be prepared by fractionation again with ethyl acetate. More specifically, the fraction is 1) immersed semi-dried turmeric in 5 to 20 times the total weight of the extraction solvent, and extracted for 1 to 12 hours at a temperature of 50 ℃ to 250 ℃; 2) filtering the extract of step 1); And 3) fractionating the filtered extract of step 2) into 1 to 3 volumes of chloroform. However, the present invention is not limited thereto.
상기 방법에 있어서, 단계 1)의 추출 용매는 물, 알코올 또는 이들의 혼합물 중 어느 하나의 용매일 수 있고, 상기 추출 용매는 물인 것이 더욱 바람직하나 이에 한정되지 아니한다. 상기 추출 용매는 울금의 총 중량의 5 내지 20배를 첨가하여 추출하는 것이 바람직하고, 울금의 총 중량의 7 내지 15배를 첨가하여 추출하는 것이 더욱 바람직하고, 울금의 총 중량의 10배를 첨가하여 추출하는 것이 가장 바람직하나, 이에 한정되지 아니한다. 상기 단계 1)의 추출 온도는 부패, 변색 및 변취를 방지하기 위하여 50℃ 내지 250℃인 것이 바람직하고, 상기 온도는 70℃ 내지 200℃인 것이 더욱 바람직하고, 상기 온도는 100℃인 것이 가장 바람직하나, 이에 한정되지 아니한다. 상기 단계 1)의 추출 시간은 1 내지 12시간인 것이 바람직하고, 상기 시간은 3 내지 10시간인 것이 더욱 바람직하며, 상기 시간은 5시간인 것이 가장 바람직하나, 이에 한정되지 아니한다. 상기 단계 1)의 추출은 열수 추출법, 중탕 추출법, 초음파 추출법, Soxhlet 추출법 및 환류냉각 추출법 등 당업계의 통상적으로 이용되는 추출방법이 모두 이용될 수 있다. 상기 방법에 있어서, 단계 2)의 여과는 당업계에서 통상적으로 이용되는 여과방법이 모두 이용될 수 있다. 특히, 단계 2)의 여과가 여과망을 이용하여 수행되는 경우, 상기 여과는 50 내지 200메쉬 여과망으로 여과하는 것이 바람직하고, 상기 여과는 70 내지 150메쉬 여과망으로 여과하는 것이 더욱 바람직하며, 상기 여과는 100 메쉬 여과망으로 여과하는 것이 가장 바람직하나, 이에 한정되지 아니한다. 상기 방법에 있어서, 단계 3)의 클로로포름은 단계 2)에서 여과된 추출물 부피의 1 내지 3배인 것이 바람직하고, 상기 부피는 1.5 내지 2.5배인 것이 더욱 바람직하며, 상기 부피는 2배인 것이 가장 바람직하나, 이에 한정되지 아니한다. 상기 방법에 있어서, 상기 분획 방법은 4) 상기 단계 3)의 클로로포름 분획물을 분리한 후, 남은 분획을 1 내지 3배 부피의 에틸아세테이트로 다시 분획하는 단계를 추가적으로 포함할 수 있으나, 이에 한정되지 아니한다. 상기 단계 4)의 에틸아세테이트는 단계 3)의 클로로포름 분획물을 분리하고 남은 분획 부피의 1 내지 3배인 것이 바람직하고, 상기 부피는 1.5 내지 2.5배인 것이 더욱 바람직하며, 상기 부피는 2배인 것이 가장 바람직하나, 이에 한정되지 아니한다.In the above method, the extraction solvent of step 1) may be any one of water, alcohol or a mixture thereof, and the extraction solvent is more preferably water, but is not limited thereto. The extraction solvent is preferably extracted by adding 5 to 20 times the total weight of turmeric, more preferably 7 to 15 times the total weight of turmeric, and 10 times of the total weight of turmeric Most preferably, but not limited thereto. The extraction temperature of step 1) is preferably 50 ° C to 250 ° C, more preferably 70 ° C to 200 ° C, and most preferably 100 ° C to prevent rot, discoloration and odor. However, the present invention is not limited thereto. The extraction time of step 1) is preferably 1 to 12 hours, more preferably 3 to 10 hours, and most preferably 5 hours, but is not limited thereto. Extraction of the step 1) may be used in the extraction method commonly used in the art, such as hot water extraction, bath extraction, ultrasonic extraction, Soxhlet extraction and reflux cooling extraction. In the above method, the filtration of step 2) may be used all the filtration method commonly used in the art. In particular, when the filtration of step 2) is carried out using a filtering network, the filtration is preferably filtered through a 50 to 200 mesh filter network, the filtration is more preferably filtered through a 70 to 150 mesh filter network, the filtration is Filtration with a 100 mesh filter net is most preferred, but not limited thereto. In the method, the chloroform of step 3) is preferably 1 to 3 times the volume of the extract filtered in step 2), more preferably 1.5 to 2.5 times the volume, most preferably 2 times the volume, It is not limited to this. In the above method, the fractionation method may further include the step of 4) separating the chloroform fraction of step 3), and then fractionating the remaining fraction again with 1 to 3 volumes of ethyl acetate, but is not limited thereto. . The ethyl acetate of step 4) is preferably 1 to 3 times the volume of the remaining fraction after separating the chloroform fraction of step 3), more preferably 1.5 to 2.5 times the volume, most preferably 2 times the volume. This is not limitative.
본 발명에 의한 울금 물 추출물의 분획물은 HepG2/2E1 세포에서 알코올에 의한 간세포의 손상을 억제하여 알코올성 간 손상의 예방에 효과가 있고, 특히 분획물 중에서도 클로로포름 분획물이 가장 뛰어난 효과를 나타낸다(도 3 및 도 4 참조). 더욱이, 상기 울금 물 추출물의 클로로포름 분획물은 HepG2/2E1 세포에서 알코올성 지질과산화물의 생성을 억제하고(도 5 참조), 항산화 활성을 증가시키는 효과가 있다(도 6 참조). 따라서, 상기 울금 물 추출물의 분획물은 알코올성 간 손상 예방용 약학적 조성물 또는 건강기능식품으로 유용하게 이용될 수 있다.
Fraction of turmeric water extract according to the present invention is effective in the prevention of alcoholic liver damage by inhibiting the damage of hepatocytes by alcohol in HepG2 / 2E1 cells, in particular chloroform fraction shows the most excellent effect among the fractions (Fig. 3 and Fig. 4). Moreover, the chloroform fraction of the turmeric water extract has the effect of inhibiting the production of alcoholic lipid peroxides in HepG2 / 2E1 cells (see FIG. 5) and increasing antioxidant activity (see FIG. 6). Therefore, the fraction of turmeric water extract may be usefully used as a pharmaceutical composition or health functional food for preventing alcoholic liver damage.
상기 약학적 조성물은 울금 물 추출물의 분획물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있고, 약학적 조성물의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 추가적으로 포함할 수 있다. 상기 담체, 부형제 및 희석제는 락토즈(lactose), 덱스트로즈(dextrose), 수크로즈(sucrose), 솔비톨(sorbitol), 만니톨(mannitol), 자일리톨(xylitol), 에리스리톨(erythritol), 말티톨(maltitol), 전분(starch), 아라비아 고무(gum Arabic), 알지네이트(alginate), 젤라틴(gelatin), 칼슘 포스페이트(calcium phosphate), 칼슘 실리케이트(calcium silicate), 셀룰로즈(cellulose), 메틸 셀룰로즈(methyl cellulose), 미정질 셀룰로스(microcrystalline cellulose), 폴리비닐 피롤리돈(polyvinyl pyrolidone), 물(water), 메틸히드록시벤조에이트(methylhydroxybenzoate), 프로필히드록시벤조에이트(propylhydroxybenzoate), 탈크(talc), 마그네슘 스테아레이트(magnesium stearate) 및 광물유(mineral oil) 등일 수 있으나, 이에 한정되지 아니한다. 상기 약학적 조성물이 제제화되는 경우, 일반적으로 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제가 사용될 수 있으나, 이에 한정되지 아니한다.The pharmaceutical composition may further contain at least one active ingredient having the same or similar function in the fraction of turmeric water extract, and additionally include appropriate carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions. Can be. The carrier, excipient and diluent are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol , Starch, gum Arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, undetermined Vaginal cellulose, polyvinyl pyrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate stearate) and mineral oil, but are not limited thereto. When the pharmaceutical composition is formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are generally used may be used, but are not limited thereto.
상기 약학적 조성물은 경구, 직장, 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 등 다양한 경로로 투여될 수 있고, 바람직하게는 경구투여될 수 있다. 상기 약학적 조성물은 실제 임상 투여 시, 투여 경로에 따라, 산제, 과립제, 정제, 캡슐제, 현탁제 등과 같은 경구투여용 제형, 또는 연고제와 같은 외용제, 좌제 및 멸균 주사용액와 같은 비경구투여용 제형으로 제형화되어 사용될 수 있다. 경구투여를 위한 고형제제는 상기 분획물에 적어도 하나 이상의 부형제, 예를 들면 칼슘카보네이트(calcium carbonate), 수크로즈(sucrose), 락토즈(lactose) 또는 젤라틴(gelatin) 등을 섞어 제조될 수 있고, 상기와 같은 단순한 부형제 외에도 마그네슘 스테아레이트(magnesium stearate), 탈크(talc)와 같은 윤활제들도 이용될 수 있다. 경구투여를 위한 액상제제는 상기 분획물에 적어도 하나 이상의 희석제 또는 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등을 섞어 제조될 수 있다. 비경구투여용 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제 등을 섞어 제조될 수 있고, 비수성용제 또는 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜(polyethylene glycol), 올리브 오일(olive oil)과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 특히, 좌제로 제형화되는 경우, 그 기재로서 위텝솔(witepsol), 폴리에틸렌 글리콜(polyethylene glycol), 트윈61(tween 61), 카카오지, 라우린지, 글리세로젤라틴(glycerogelatin) 등이 이용될 수 있다.The pharmaceutical composition may be administered by various routes such as oral, rectal, intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular, preferably orally administered. The pharmaceutical composition may be formulated for oral administration such as powders, granules, tablets, capsules, suspensions, or parenteral dosage forms such as ointments, external preparations, suppositories, and sterile injectable solutions, depending on the route of administration during actual clinical administration. Can be formulated and used. Solid preparations for oral administration may be prepared by mixing at least one excipient such as calcium carbonate, sucrose, lactose or gelatin in the fraction. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration may be prepared by mixing at least one diluent or excipient such as wetting agents, sweeteners, fragrances, preservatives and the like in the fractions. Preparations for parenteral administration may be prepared by mixing a sterile aqueous solution, a non-aqueous solvent, a suspending agent, an emulsion, a lyophilizer, and the like. As the non-aqueous solvent or suspending agent, propylene glycol, polyethylene glycol, and olive oil may be used. vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used. In particular, when formulated as suppositories, witepsol, polyethylene glycol, tween 61, cacao butter, laurin butter, glycerogelatin, and the like may be used as the substrate. .
상기 약학적 조성물의 바람직한 투여량은 환자의 나이, 상태, 체중, 질병의 정도, 약물의 형태, 투여경로 및 시간에 따라 차이가 있으나, 일반적으로 바람직한 효과를 위한 유효성분의 투여 용량은 0.001 내지 1㎎/㎏, 바람직하게는 0.001 내지 0.1㎎/㎏의 양이 투여되도록 하며, 의사 또는 약사의 판단에 따라 일정시간 간격으로 1일 수회, 바람직하게는 1회 내지 6회 분할 투여할 수 있다.
Preferred dosages of the pharmaceutical compositions vary depending on the age, condition, weight, degree of disease, type of drug, route of administration, and time of the patient. Generally, the dosage of the active ingredient for the desired effect is 0.001 to 1 The amount of mg / kg, preferably 0.001 to 0.1mg / kg is to be administered, it can be divided into several times a day, preferably 1 to 6 times at regular intervals according to the judgment of the doctor or pharmacist.
상기 건강기능식품은 식품학적으로 허용된 담체와 혼합하여 제공될 수 있고, 제공되는 식품의 종류는 특별히 제한되지 아니한다. 상기 울금 물 추출물의 분획물을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿류, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료의 형태로 제공될 수 있다. 음료로 제형화할 경우, 울금 물 추출물의 분획물 이외에 첨가되는 액체 성분으로는 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있으나, 이에 한정되지는 아니한다. 상기 천연 탄수화물의 예는 모노사카라이드(예, 포도당, 과당 등), 디사카라이드(예, 말토오스, 수크로오스 등) 및 폴리사카라이드(예, 덱스트린, 시클로덱스트린 등과 같은 통상적인 당), 및 자일리톨, 소르비톨, 에리스리톨 등의 당 알코올이다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖ 당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다. 상술한 것 이외의 향미제로서 천연 향미제[타우마린, 스테비아 추출물 (예, 레바우디오시드 A, 글리시르히진 등)] 및 합성 향미제(예, 사카린, 아스파르탐 등)를 사용할 수 있다. 다른 양태로서, 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 증진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 또한 상기 건강기능식품은 과일 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 단독으로 또는 조합으로 사용될 수 있으며, 이러한 첨가제의 비율은 조성물 전체 중량당 0.001 내지 50 중량부의 범위에서 선택되는 것이 일반적이다.
The health functional food may be provided in admixture with a food acceptable carrier, the type of food provided is not particularly limited. Examples of the food to which the fraction of the turmeric water extract can be added include meat, sausage, bread, chocolate, candy, snacks, confectionary, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks , Tea, drink, alcoholic beverages and vitamin complexes, and the like, and may be provided in the form of powders, granules, tablets, capsules or beverages. When formulated as a beverage, the liquid component added in addition to the fraction of turmeric water extract may contain various flavors or natural carbohydrates as additional components, such as conventional beverages, but is not limited thereto. Examples of such natural carbohydrates include monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.) and polysaccharides (e.g. conventional sugars such as dextrin, cyclodextrin, etc.), and xylitol, Sugar alcohols such as sorbitol and erythritol. The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention. As flavoring agents other than those mentioned above, natural flavoring agents (taumarin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) can be used. . In another embodiment, the food composition of the present invention comprises various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, colorants and enhancers (such as cheese, chocolate), pectic acid and salts thereof, organic acids , Protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The dietary supplement may also contain pulp for the production of fruit and vegetable beverages. These components may be used singly or in combination, and the proportion of such additives is generally selected in the range of 0.001 to 50 parts by weight based on the total weight of the composition.
이하, 본 발명을 실시예 및 제조예에 의하여 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Examples and Production Examples.
단, 하기 실시예 및 제조예는 본 발명을 구체적으로 예시하는 것이며, 본 발명의 내용이 하기 실시예 및 제조예에 의해 한정되지 아니한다.
However, the following Examples and Preparation Examples specifically illustrate the present invention, and the contents of the present invention are not limited by the following Examples and Preparation Examples.
울금 추출물 및 그에 대한 분획물의 제조Preparation of turmeric extract and fractions thereof
<1-1> 울금의 물 추출물 제조<1-1> Preparation of Water Extract of Turmeric
반건조된 울금(Curcuma Longa L.)(진도, 전라남도, 한국)의 뿌리 40㎏를 정제수 400ℓ에 침지시킨 후, 산업용 추출기((주)명일이엔지)를 이용하여 100℃ 및 750mmHg의 조건에서 5시간 동안 추출한 다음, 100 메쉬의 여과망으로 여과하고, 55 내지 60℃ 및 15mmHg의 조건에서 100ℓ로 감압농축한 후, 0.5 torr 및 -35℃의 조건에서 6시간 동안 동결건조함(LYOPH-PRIDE 100R, (주)영일이엔지)으로써 울금의 물 추출물을 수득하였다.After dipping 40 kg of semi-dried Curcuma Longa L. (Jindo, Jeollanam-do, Korea) into 400 liters of purified water, use an industrial extractor (Myeongil E & C) for 5 hours at 100 ℃ and 750mmHg. After extraction, the resultant was filtered through a 100 mesh filter, concentrated under reduced pressure to 100 l at 55 to 60 ° C. and 15 mm Hg, and then lyophilized for 6 hours at 0.5 torr and −35 ° C. (LYOPH-PRIDE 100R, ( Note) Youngil ENG) to obtain a water extract of turmeric.
<1-2> 울금의 물 추출물에 대한 분획물의 제조<1-2> Preparation of Fractions for Water Extracts of Turmeric
상기 <1-1>에서 감압농축된 100ℓ의 물 추출물에 200ℓ의 클로로포름(chloroform)을 첨가하여 물층과 클로로포름층이 분리되도록 방치하였다. 화학평형이 이루어진 후 클로로포름층을 분리하였고, 이를 55 내지 60℃ 및 15mmHg의 조건에서 감압농축하여 용매를 전량 제거한 다음, 이를 1㎖의 클로로포름에 다시 녹여 회수하고 질소 가스로 클로로포름을 전량 제거함으로써 울금의 물 추출물에 대한 클로로포름 분획물(CLH-C)을 수득하였다. In <1-1>, 200 liters of chloroform was added to 100 liters of the water extract concentrated under reduced pressure, and the water layer and the chloroform layer were left to separate. After chemical equilibration, the chloroform layer was separated and concentrated under reduced pressure at 55 to 60 ° C. and 15 mmHg to remove all the solvent, and then dissolved and recovered in 1 ml of chloroform. The chloroform was removed by nitrogen gas to remove all the chloroform. Chloroform fraction (CLH-C) was obtained for the water extract.
상기와 같은 클로로포름 분획물의 제조 과정에서, 클로로포름층을 분리해 내고 남은 물층에 200ℓ의 에틸아세테이트(ethyl acetate)를 첨가하여 물층과 에틸아세테이트층이 분리되도록 방치하였다. 화학평형이 이루어진 후, 에틸아세테이트 층을 분리하였고, 이를 55 내지 60℃ 및 15mmHg의 조건에서 감압농축하여 용매를 전량 제거한 다음, 이를 1㎖의 에틸아세테이트에 다시 녹여 회수하고 질소 가스로 클로로포름을 전량 제거함으로써 에틸아세테이트 분획물(CLH-E)을 수득하였다.In the process of preparing the chloroform fraction as described above, the chloroform layer was separated and 200 L of ethyl acetate was added to the remaining water layer, and the water layer and the ethyl acetate layer were left to separate. After chemical equilibration, the ethyl acetate layer was separated, concentrated under reduced pressure at 55 to 60 ° C. and 15 mm Hg to remove all solvents, and then dissolved and recovered in 1 ml of ethyl acetate. The total amount of chloroform was removed with nitrogen gas. This yielded an ethyl acetate fraction (CLH-E).
물 추출물의 간 손상 예방 효과 측정Measurement of liver damage prevention effect of water extract
<2-1> <2-1> InIn VitroVitro 실험 Experiment
실시예 1의 <1-1>에서 수득한 물 추출물의 알코올성 간 손상 예방 효과를 확인하기 위하여 XTT 분석을 수행하였다. 24-웰 플레이트에 5×104개/웰의 밀도로 HepG2/2E1 세포주(HepG2(ATCC, Manassas VA U.S.A 구입처)세포에 CYP2E1 유전자를 삽입하여 재조합된 세포)를 분주하여 1㎖의 MEM 배지(Hyclone)에서 16시간 동안 배양한 후, 15㎍/㎖ 또는 30㎍/㎖의 물 추출물, 300mM의 에탄올 및 3%의 FBS를 함유한 배지로 교환하여 24시간 동안 37℃에서 배양하기를 5일 동안 반복하였다. 7일째 되는 날에 추출물과 에탄올 및 FBS가 함유된 배지를 모두 제거하고, XTT-PMS 용액(1㎎의 XTT(sigma)와 100mM의 PMS(sigma)의 혼합 용액)을 넣어 2시간 동안 반응시킨 후, 450nm에서 흡광도를 측정하여 세포 생존도를 확인하였다(BIO-TEK). 음성대조군에서는 3%의 FBS만이 함유된 배지만으로 배양하였고, 양성대조군에서는 배양액과 300mM의 에탄올 및 3%의 FBS가 함유된 배지로 배양하였다.XTT analysis was performed to confirm the alcoholic liver damage prevention effect of the water extract obtained in <1-1> of Example 1. Dispense 1 ml of MEM medium (Hyclone) into a HepG2 / 2E1 cell line (cells recombined by inserting the CYP2E1 gene into HepG2 (ATCC, Manassas VA USA) cells) at a density of 5 × 10 4 / well in a 24-well plate. Incubated for 16 hours, followed by incubation for 24 hours at 37 ° C. for 5 days, exchanged with medium containing 15 μg / ml or 30 μg / ml water extract, 300 mM ethanol and 3% FBS. It was. On the 7th day, the extract, ethanol and FBS-containing medium were all removed and reacted for 2 hours by adding XTT-PMS solution (1 mg of XTT (sigma) and 100 mM PMS (sigma)). , Absorbance was measured at 450nm to confirm cell viability (BIO-TEK). In the negative control group, only 3% of FBS was cultured. Only the positive control group was cultured with a medium containing 300 mM ethanol and 3% FBS.
그 결과, 양성대조군에서는 음성대조군 대비 45%의 세포 생존도를 나타내는 반면, 15㎍/㎖의 물 추출물을 첨가한 배지에서 배양한 실험군 및 30㎍/㎖의 물 추출물을 첨가한 배지에서 배양한 실험군에서는 각각 65% 및 80%의 세포 생존도를 나타내었다(도 1).As a result, the positive control group showed 45% cell viability compared to the negative control group, while the experimental group cultured in the medium to which the 15 µg / ml water extract was added and the experimental group cultured in the medium to which the 30 µg / mL water extract was added. Showed cell viability of 65% and 80%, respectively (FIG. 1).
상기와 같은 결과로부터, 울금의 물 추출물은 알콜성 간 손상에 대한 예방 효과를 나타냄을 알 수 있고, 이러한 울금의 물 추출물의 효과는 투여량에 의존적인 경향을 나타냄을 알 수 있다.From the above results, it can be seen that the water extract of turmeric shows a prophylactic effect against alcoholic liver damage, and the effect of the water extract of turmeric shows a dose-dependent tendency.
<2-2> <2-2> InIn VivoVivo 실험 Experiment
실시예 1의 <1-1>에서 수득한 물 추출물의 알코올성 간 손상 예방 효과를 확인하고자 동물실험을 수행하였다. 32마리의 C57BL/6 수컷 마우스(오리엔트 바이오, 경기도, 한국)를 7일 동안 실험실 환경(온도 23±3℃, 상대습도 55±15%, 환기횟수 10~20회/hr, 12시간 간격의 조명 주기, 조도 150~300Lux의 환경)에 적응하도록 순화시키고 사료와 물을 충분히 공급하면서 사육하였다.Animal experiments were performed to determine the alcoholic liver damage prevention effect of the water extract obtained in <1-1> of Example 1. Thirty-two C57BL / 6 male mice (Oriental Bio, Gyeonggi-do, Korea) were illuminated for 7 days in a laboratory environment (temperature 23 ± 3 ° C, relative humidity 55 ± 15%, ventilation times 10-20 times / hr, 12-hour illumination Cycle, roughness 150 ~ 300Lux) to acclimatize and were fed with sufficient feed and water.
상기 32마리의 마우스를 몸무게가 동일하도록 적절히 분배하여 4개의 군(각 8마리씩)으로 나눈 후, 하기 표 1과 같이 실험을 진행하였다. 제1군의 마우스들은 10일 동안 증류수만을 경구투여하여 음성대조군으로서 이용되었고, 제2군의 마우스들은 7일 동안 증류수를 경구투여한 후, 8일, 9일 및 10일째에는 5g/㎏/day의 에탄올을 녹인 증류수를 경구투여하여 양성대조군으로서 이용하였다. 실험군인 제3군과 제4군의 마우스들에는 7일 동안 각각 100㎎/㎏/day과 500㎎/㎏/day의 상기 울금의 물 추출물을 녹인 증류수를 경구투여한 후, 8일, 9일 및 10일째에는 각각 5g/㎏/day의 에탄올과 100㎎/㎏/day의 물 추출물을 녹인 증류수 및 5g/㎏/day의 에탄올과 500㎎/㎏/day의 물 추출물을 녹인 증류수를 12시간 간격으로 5회에 걸쳐 경구투여하였다. 5회째 투여 6시간 후, 각 마우스들에서 혈청을 수득하고, 실험 전까지 -20℃에서 보관하였다.The 32 mice were divided into four groups (eight animals each) by appropriately distributing the same weights, and then the experiments were performed as shown in Table 1 below. The first group of mice was used as a negative control group by oral administration of distilled water only for 10 days, and the second group of mice was orally administered distilled water for 7 days, and then 5 g / kg / day on the 8th, 9th and 10th days. Distilled water dissolved in ethanol was orally administered and used as a positive control group. The mice of the experimental group 3 and 4 groups were orally administered distilled water dissolved in the turmeric water extract of 100 mg / kg / day and 500 mg / kg / day for 7 days, respectively, 8 days, 9 days On the 10th day, distilled water dissolved in 5g / kg / day ethanol and 100mg / kg / day water extract and distilled water dissolved in 5g / kg / day ethanol and 500mg / kg / day water extract were 12 hours apart. Orally administered five times. Six hours after the fifth dose, serum was obtained from each mouse and stored at −20 ° C. until the experiment.
1일 ~ 7일1 to 7 days
8일, 9일, 10일8 days, 9 days, 10 days
(12시간 간격으로 5회 투여)(5 doses every 12 hours)
제1군(n=8)
1st group (n = 8)
증류수
Distilled water
증류수
Distilled water
제2군(n=8)
2nd group (n = 8)
증류수
Distilled water
증류수에 에탄올(5g/㎏/day)을
녹여서 투여
Ethanol (5 g / kg / day) was added to distilled water.
Dissolve and administer
제3군(n=8)
3rd group (n = 8)
증류수에
물 추출물(100㎎/㎏/day)을
녹여서 투여
In distilled water
Water extract (100mg / kg / day)
Dissolve and administer
증류수에 에탄올(5g/㎏/day)과
물 추출물(100㎎/㎏/day)을
녹여서 투여
Ethanol (5 g / kg / day) and
Water extract (100mg / kg / day)
Dissolve and administer
제4군(n=8)
4th group (n = 8)
증류수에
물 추출물(500㎎/㎏/day)을
녹여서 투여
In distilled water
Water extract (500mg / kg / day)
Dissolve and administer
증류수에 에탄올(5g/㎏/day)과
물 추출물(500㎎/㎏/day)을
녹여서 투여
Ethanol (5 g / kg / day) and
Water extract (500mg / kg / day)
Dissolve and administer
상기와 같이 각 군의 마우스들로부터 수득한 혈청에서 ALT(alanine aminotransferase)의 활성을 측정 및 비교하였다. 그 결과, 음성대조군인 제1군에서는 ALT의 활성이 13.62 IU/L로 나타나는 반면, 양성대조군인 제2군에서는 ALT의 활성이 85.13 IU/L까지 올라가는 심각한 간 손상을 보였다. 그에 반하여 동일하게 5g/㎏/day의 에탄올을 투여하였음에도, 울금의 물 추출물을 미리 투여하고 에탄올을 투여하는 동안에도 울금의 물 추출물을 지속적으로 투여한 제3군 및 제4군의 마우스들은 각각 19.08 IU/L 및 14.18 IU/L로 음성대조군과 거의 동일/유사한 ALT 활성을 나타내는 것으로 확인되었다(도 2).As described above, the activity of ALT (alanine aminotransferase) in the serum obtained from each group of mice was measured and compared. As a result, the ALT activity was 13.62 IU / L in the negative control group 1, whereas the ALT activity was increased to 85.13 IU / L in the positive control group 2, and showed severe liver damage. On the other hand, mice in the third and fourth groups, which were administered the same with 5 g / kg / day of ethanol, were continuously administered the turmeric water extract during the administration of turmeric water extract in advance and 19.08, respectively. IU / L and 14.18 IU / L were found to show nearly the same / similar ALT activity as the negative control (FIG. 2).
상기와 같은 결과로부터, 울금의 물 추출물이 알콜성 간 손상에 대한 예방 효과를 나타냄을 알 수 있다.From the above results, it can be seen that the water extract of turmeric shows a protective effect against alcoholic liver damage.
울금의 물 추출물에 대한 분획물의 간 손상 예방 효과 측정Measurement of liver damage prevention effect of fractions on water extract of turmeric
실시예 1의 <1-2>에서 수득한 분획물들의 알코올성 간손상 예방 효과를 확인하기 위하여 XTT 분석을 수행하였다. 24-웰 플레이트에 5×104개/웰의 밀도로 HepG2/2E1 세포주(HepG2(ATCC, Manassas VA U.S.A 구입처)세포에 CYP2E1 유전자를 삽입하여 재조합된 세포)를 분주하여 1㎖의 MEM 배지(Hyclone)에서 16시간 동안 배양한 후, 10㎍/㎖의 클로로포름 또는 에틸아세테이트 분획물, 300mM의 에탄올 및 3%의 FBS를 함유한 배지로 교환하여 24시간 동안 37℃에서 배양하기를 5일 동안 반복하였다. 7일째 되는 날에 분획물과 에탄올 및 FBS가 함유된 배지를 모두 제거하고, XTT-PMS 용액(1㎎의 XTT(sigma)와 100mM(sigma)의 혼합 용액)을 넣어 2시간 동안 반응시킨 후, 450nm에서 흡광도를 측정하여 세포 생존도를 확인하였다(BIO-TEK). 음성대조군에서는 3%의 FBS만이 함유된 배지만으로 배양하였고, 양성대조군에서는 배양액과 300mM의 에탄올 및 3%의 FBS가 함유된 배지로 배양하였다. 아울러, 울금의 물 추출물과의 효능을 비교하기 위하여, 동량의 울금 물 추출물이 포함된 배지에서 배양한 실험군에서도 세포 생존도를 확인하였다.XTT analysis was performed to confirm the alcoholic liver damage prevention effect of the fractions obtained in <1-2> of Example 1. Dispense 1 ml of MEM medium (Hyclone) into a HepG2 / 2E1 cell line (cells recombined by inserting the CYP2E1 gene into HepG2 (ATCC, Manassas VA USA) cells) at a density of 5 × 10 4 / well in a 24-well plate. After 16 hours of incubation, incubation at 37 ° C. for 24 hours was repeated for 5 days by exchanging with a medium containing 10 μg / ml of chloroform or ethyl acetate fraction, 300 mM ethanol and 3% FBS. On the 7th day, remove all the fractions, the medium containing ethanol and FBS, add XTT-PMS solution (1 mg of XTT (sigma) and 100 mM (sigma) mixed solution) and react for 2 hours. Absorbance was measured in order to confirm cell viability (BIO-TEK). In the negative control group, only 3% of FBS was cultured. Only the positive control group was cultured with a medium containing 300 mM ethanol and 3% FBS. In addition, in order to compare the efficacy of turmeric with water extract, the cell viability was also confirmed in the experimental group cultured in the medium containing the same amount of turmeric water extract.
그 결과, 양성대조군에서는 음성대조군 대비 40%의 세포 생존도를 나타내는 반면, 물 추출물을 첨가한 배지에서 배양한 실험군, 클로로포름 분획물을 첨가한 배지에서 배양한 실험군 및 에틸아세테이트 분획물을 첨가한 배지에서 배양한 실험군에서는 각각 57%, 74% 및 58%의 세포 생존도를 나타내었다(도 3).As a result, the positive control group showed 40% cell viability compared to the negative control group, while the experimental group cultured in the medium containing the water extract, the experimental group cultured in the medium containing the chloroform fraction, and the culture medium containing the ethyl acetate fraction were added. One experimental group showed cell viability of 57%, 74% and 58%, respectively (FIG. 3).
동일한 방법으로, 50 ㎍/㎖의 울금 클로로포름 분획층과 울금 에틸아세테이트 분획층을 비교한 결과에서도 양성대조군에서는 음성대조군 대비 60%의 세포 생존도를 나타내는 반면, 울금 클로로포름 분획물을 첨가한 배지에서 배양한 실험군 및 에틸아세테이트 분획물을 첨가한 배지에서 배양한 실험군에서는 각각 92% 및 69%의 세포 생존도를 나타내었다(도 4).In the same way, 50 μg / ml turmeric chloroform fractionation layer and turmeric ethyl acetate fractionation layer also showed 60% cell viability in the positive control group compared to the negative control group, while cultured in medium containing turmeric chloroform fraction. The experimental group and the experimental group cultured in the medium to which the ethyl acetate fraction was added showed cell viability of 92% and 69%, respectively (FIG. 4).
상기와 같은 결과로부터, 울금의 물 추출물에 대한 분획물은 알콜성 간 손상에 대한 예방 효과를 나타냄을 알 수 있고, 분획물 중에서도 클로로포름 분획물의 효과가 가장 뛰어남을 알 수 있다.From the above results, it can be seen that the fraction of the water extract of turmeric shows a prophylactic effect against alcoholic liver damage, and it can be seen that the effect of the chloroform fraction is the most excellent among the fractions.
클로로포름 분획물의 지질과산화물 생성 억제 효과 측정Inhibition of Lipid Peroxide Production by Chloroform Fraction
상기 실시예 3에서 알콜성 간 손상에 대한 예방 효과가 가장 뛰어난 것으로 확인된 클로로포름 분획물의 지질과산화물 생성 억제 효과를 측정하기 위하여, 지질과산화물인 말론디알데하이드(malondialdehyde, MDA)의 생성 농도를 측정하였다. MDA의 농도 측정을 위하여 1×106개의 HepG2/2E1 세포에 50㎍/㎖의 클로로포름 분획물을 처리하여 3일 동안 배양한 후, 세포를 회수(harvest)하여 passive lysis buffer(Promega)를 이용하여 세포를 용해시켰다. 상기와 같이 용해시킨 세포 용해물을 4℃, 14000rpm에서 5분간 원심분리하여 단백질을 수득하였고, 수득된 단백질을 Bradford 방법으로 정량하였다. 정량된 단백질 0.5㎖와 15%의 TCA(trichloroacetic acid) 0.25㎖을 넣고 상온에서 10분 동안 반응시킨 후, 3000rpm에서 10분 동안 원심분리한 후, 상층액 0.5㎖와 0.37% TBA(thiobarbituric acid) 0.5㎖를 혼합하여 100℃의 수욕상에서 30분간 가열한 후, 얼음 수욕상에 넣어 반응을 중지시켰다. 그런 다음, 3000rpm에서 10분간 원심분리하여 상층액을 취하여 535nm에서 흡광도를 측정하였다. 음성대조군에서는 3%의 FBS만이 함유된 배지만으로 배양하였고, 양성대조군에서는 배양액과 300mM의 에탄올 및 3%의 FBS가 함유된 배지로 배양하였다.In order to measure the effect of inhibiting the formation of lipid peroxides of the chloroform fraction, which was found to have the best preventive effect against alcoholic liver damage in Example 3, the production concentration of malondialdehyde (MDA), a lipid peroxide, was measured. In order to measure the concentration of MDA, 1 × 10 6 HepG2 / 2E1 cells were treated with 50 μg / ml of chloroform fractions and incubated for 3 days, and then the cells were harvested and harvested using passive lysis buffer (Promega). Was dissolved. The lysed cell lysate was centrifuged at 4 ° C. and 14000 rpm for 5 minutes to obtain a protein, and the obtained protein was quantified by the Bradford method. After adding 0.5 ml of quantified protein and 0.25 ml of 15% trichloroacetic acid (TCA) for 10 minutes at room temperature, centrifuging at 3000 rpm for 10 minutes, supernatant 0.5 ml and 0.37% TBA (thiobarbituric acid) 0.5 After the mixture was mixed and heated for 30 minutes in a 100 DEG C water bath, the reaction mixture was stopped in an ice water bath. Then, the supernatant was taken by centrifugation at 3000 rpm for 10 minutes and the absorbance was measured at 535 nm. In the negative control group, only 3% of FBS was cultured. Only the positive control group was cultured with a medium containing 300 mM ethanol and 3% FBS.
그 결과, 음성대조군에서는 200nmol/㎎의 MDA가, 양성대조군에서는 390nmol/㎎의 MDA가 검출되었고, 클로로포름 분획물을 처리한 실험군에서는 280nmol/㎎의 MDA가 검출되었다(도 5).As a result, 200 nmol / mg MDA was detected in the negative control group and 390 nmol / mg MDA in the positive control group, and 280 nmol / mg MDA was detected in the experimental group treated with the chloroform fraction (FIG. 5).
상기와 같은 결과로부터, 울금의 물 추출물에 대한 클로로포름 분획물이 알코올에 의한 과산화지질의 생성을 억제함을 알 수 있고, 과산화지질의 생성 억제를 통하여 알코올성 간 손상을 예방할 수 있음을 알 수 있다.From the above results, it can be seen that the chloroform fraction of the water extract of turmeric inhibits the production of lipid peroxide by alcohol, and it can be seen that alcoholic liver damage can be prevented through the inhibition of the production of lipid peroxide.
클로로포름 분획물의 항산화 활성을 측정하기 위하여, 1×106개의 HepG2/2E1 세포에 50㎍/㎖의 클로로포름 분획물을 처리하여 3일 동안 배양한 후, 세포를 회수(harvest)하여 passive lysis buffer(Promega)를 이용하여 세포를 용해시켰다. 상기와 같이 용해시킨 세포 용해물을 4℃, 14000rpm에서 5분간 원심분리하여 단백질을 수득하였고, 수득된 단백질을 Bradford 방법으로 정량한 후, CAT(catalase)(Aebi et al., 방법(Method Enzymol. 105:121-126), GST(glutathion-S-transferase)(Habig et al., Method Enzymol. 77: 398-405), SOD(superoxide dismutase)(McCord et al., 방법(J. Biol. Chem. 244: 6049-6055), GPx(glutathione peroxidase)(Thomson et al., Br. J. Nutr. 69: 577-588), GR(glutathion reductase)(Worthington et al., Eur. J. Biochem. 67: 231-238)의 효소 활성 및 환원 GSH(reduced glutathion)(Akerboom et al., Method Enzymol. 77: 373-382)의 농도를 측정하였다. 음성대조군에서는 3%의 FBS만이 함유된 배지만으로 배양하였고, 양성대조군에서는 배양액과 300mM의 에탄올 및 3%의 FBS가 함유된 배지로 배양하였다.In order to measure the antioxidant activity of the chloroform fractions, 1 × 10 6 HepG2 / 2E1 cells were treated with 50 μg / ml chloroform fractions and incubated for 3 days, after which the cells were harvested and passive lysis buffer (Promega). Cells were lysed using. The lysed cell lysate was centrifuged at 4 ° C. and 14000 rpm for 5 minutes to obtain a protein, and the protein obtained was quantified by Bradford method, followed by CAT (catalase) (Aebi et al., Method Enzymol. 105: 121-126), glutathion-S-transferase (GST) (Habig et al., Method Enzymol. 77: 398-405), superoxide dismutase (SOD) (McCord et al., Method (J. Biol. Chem. 244: 6049-6055), Glutathione peroxidase (GPx) (Thomson et al., Br. J. Nutr. 69: 577-588), Glutathion reductase (GR) (Worthington et al., Eur. J. Biochem. 67: 231-238) enzyme activity and reduced glutathion (GSH) (Akerboom et al., Method Enzymol. 77: 373-382) were measured in the negative control group cultured with only 3% FBS medium, In the positive control group, the culture medium was cultured with 300 mM ethanol and 3% FBS.
그 결과, 양성대조군에 비하여 클로로포름 분획물을 처리한 실험군에서 상기 CAT, GST, SOD, GPx 및 GR 효소들의 활성 및 환원 GSH의 농도가 증가되는 것을 확인하였다(도 6).As a result, it was confirmed that the activity of the CAT, GST, SOD, GPx and GR enzymes and the concentration of reducing GSH was increased in the experimental group treated with the chloroform fraction compared to the positive control group (Fig. 6).
상기와 같은 결과로부터 울금의 물 추출물에 대한 클로로포름 분획물이 항산화 활성을 가짐을 알 수 있고, 이러한 항산화 활성으로 인해 알코올성 간 손상을 예방할 수 있음을 알 수 있다.
From the above results, it can be seen that the chloroform fraction of the water extract of turmeric has antioxidant activity, and it can be seen that alcoholic liver damage can be prevented due to such antioxidant activity.
<제조예 1> 약학적 조성물의 제조Preparation Example 1 Preparation of Pharmaceutical Composition
<1-1> 시럽제의 제조<1-1> Preparation of Syrup
울금 물 추출물의 클로로포름 분획물을 유효성분으로 함유하는 시럽제는 다음 표 2의 조성과 같이 제조하였다.Syrup containing chloroform fraction of turmeric water extract as an active ingredient was prepared as shown in Table 2.
<1-2> 정제의 제조<1-2> Preparation of tablets
울금 물 추출물의 클로로포름 분획물을 유효성분으로 함유하는 정제는 표 3의 조성과 같이 제조하였다.Tablets containing the chloroform fraction of turmeric water extract as an active ingredient were prepared as shown in Table 3.
실시예 <1-2>의 클로로포름 분획물 250 중량부, 락토오스 175.9 중량부, 감자전분 180 중량부 및 콜로이드성 규산 32 중량부와 혼합하였다. 상기 혼합물에 10% 젤라틴 용액을 첨가시킨 후, 분쇄하여 14 매쉬체를 통과시켰다. 이것을 건조하고 여기에 감자전분 160 중량부, 활석 50 중량부 및 스테아린산 마그네슘 5 중량부를 첨가하여 얻은 혼합물을 정제로 제조하였다.250 parts by weight of the chloroform fraction of Example <1-2>, 175.9 parts by weight of lactose, 180 parts by weight of potato starch and 32 parts by weight of colloidal silicic acid were mixed. 10% gelatin solution was added to the mixture, which was then ground and passed through a 14 mesh sieve. This was dried and the mixture obtained by adding 160 parts by weight of potato starch, 50 parts by weight of talc and 5 parts by weight of magnesium stearate was prepared as a tablet.
<제조예 2> 식품의 제조Production Example 2 Preparation of Food
본 발명의 울금 물 추출물의 클로로포름 분획물을 함유하는 식품들을 다음과 같이 제조하였다.Foods containing the chloroform fraction of turmeric water extract of the present invention were prepared as follows.
<2-1> 밀가루 식품의 제조<2-1> Production of flour food
본 발명의 실시예 <1-2>의 클로로포름 분획물 0.5 ~ 5.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.5 to 5.0 parts by weight of the chloroform fraction of Example <1-2> of the present invention was added to the flour, and bread, cake, cookies, crackers, and noodles were prepared using the mixture to prepare foods for health promotion.
<2-2> 유제품의 제조<2-2> Production of Dairy Products
본 발명의 실시예 <1-2>의 클로로포름 분획물 5 ~ 10 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.5 to 10 parts by weight of the chloroform fraction of Example <1-2> of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
<2-3> 선식의 제조<2-3> Preparation of Wire
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.
본 발명의 실시예 <1-2>의 클로로포름 분획물을 진공 농축기에서 감압 농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The chloroform fraction of Example <1-2> of the present invention was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by spraying and drying with a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 울금 물 추출물의 클로로포름 분획물의 건조분말을 다음의 비율로 배합하여 제조하였다.The dry powders of the chloroform fractions of the grains, seeds and turmeric water extracts prepared above were formulated in the following ratios.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
실시예 <1-2>의 클로로포름 분획물 건조분말(3 중량부),Chloroform fraction dry powder of Example <1-2> (3 parts by weight),
영지(0.5 중량부) 및Ganoderma lucidum (0.5 parts by weight) and
지황(0.5 중량부)
(0.5 parts by weight)
이상, 본 발명의 바람직한 실시예를 들어 상세하게 설명하였으나, 본 발명은 상기 실시예에 한정되지 않고, 본 발명의 기술적 사상 및 범위 내에서 당업자에 의하여 여러 가지 변형 및 변경이 가능하다.As mentioned above, although preferred embodiment of this invention was described in detail, this invention is not limited to the said embodiment, A various deformation | transformation and a change are possible for those skilled in the art within the technical idea and range of this invention.
Claims (7)
7. The dietary supplement for preventing alcoholic liver damage according to claim 6, wherein the fraction is a chloroform fraction of turmeric water extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110081853A KR20130019725A (en) | 2011-08-17 | 2011-08-17 | A pharmaceutical composition comprising the fractions of water extract from curcuma longa l. for preventing alcoholic liver damage |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110081853A KR20130019725A (en) | 2011-08-17 | 2011-08-17 | A pharmaceutical composition comprising the fractions of water extract from curcuma longa l. for preventing alcoholic liver damage |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20130019725A true KR20130019725A (en) | 2013-02-27 |
Family
ID=47897784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110081853A KR20130019725A (en) | 2011-08-17 | 2011-08-17 | A pharmaceutical composition comprising the fractions of water extract from curcuma longa l. for preventing alcoholic liver damage |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20130019725A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103520636A (en) * | 2013-09-27 | 2014-01-22 | 青岛绿曼生物工程有限公司 | Pure traditional Chinese medicine composition for treatment of duck virus hepatitis and preparation method thereof |
CN104189774A (en) * | 2014-09-19 | 2014-12-10 | 宋秀花 | Traditional Chinese medicine for treating chronic hepatitis B |
JP2015143200A (en) * | 2013-12-27 | 2015-08-06 | ハウスウェルネスフーズ株式会社 | Inhibitors of vcam-1 expression |
CN105265919A (en) * | 2014-07-01 | 2016-01-27 | 好侍食品集团本社株式会社 | Production method of beverage with useful components of rhizoma curcumae longae |
CN116474070A (en) * | 2023-04-23 | 2023-07-25 | 江苏恰瑞生物科技有限公司 | Preparation method of blood perfusion filler for treating acute alcoholic liver injury |
-
2011
- 2011-08-17 KR KR1020110081853A patent/KR20130019725A/en not_active Application Discontinuation
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103520636A (en) * | 2013-09-27 | 2014-01-22 | 青岛绿曼生物工程有限公司 | Pure traditional Chinese medicine composition for treatment of duck virus hepatitis and preparation method thereof |
JP2015143200A (en) * | 2013-12-27 | 2015-08-06 | ハウスウェルネスフーズ株式会社 | Inhibitors of vcam-1 expression |
JP2019019143A (en) * | 2013-12-27 | 2019-02-07 | ハウスウェルネスフーズ株式会社 | Inhibitors of vcam-1 expression |
JP2019019142A (en) * | 2013-12-27 | 2019-02-07 | ハウスウェルネスフーズ株式会社 | Inhibitors of vcam-1 expression |
CN105265919A (en) * | 2014-07-01 | 2016-01-27 | 好侍食品集团本社株式会社 | Production method of beverage with useful components of rhizoma curcumae longae |
CN104189774A (en) * | 2014-09-19 | 2014-12-10 | 宋秀花 | Traditional Chinese medicine for treating chronic hepatitis B |
CN116474070A (en) * | 2023-04-23 | 2023-07-25 | 江苏恰瑞生物科技有限公司 | Preparation method of blood perfusion filler for treating acute alcoholic liver injury |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20120002131A (en) | Composition for treating or preventing obesity containing curcuma longa extract | |
KR20130019725A (en) | A pharmaceutical composition comprising the fractions of water extract from curcuma longa l. for preventing alcoholic liver damage | |
KR20200002260A (en) | Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts | |
KR101117301B1 (en) | A composition comprising the fermented rhizoma of curcuma aromatica salisb for treating and preventing alcoholic liver disease | |
KR20220132349A (en) | Composition for preventing, ameliorating or treating metabolic disease comprising leaf extract of new pepper cultivar as effective component | |
KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
KR101688002B1 (en) | Composition for preventing or treating liver diseases comprising sonicated ginseng berry | |
JP2007519715A (en) | A composition comprising a kabonashi extract, a dangwei extract, or a mixed herbal extract thereof as an active ingredient | |
KR102436692B1 (en) | Composition comprising steamed mature silkworm products having silk protein for preventing or treating obesity | |
KR100586269B1 (en) | Composition comprising Lindera obtusiloba extract | |
KR102204912B1 (en) | Pharmaceutical Composition Comprising Fraction of Ginseng Extract for Preventing or Treating Liver Diseases | |
KR100590726B1 (en) | Composition comprising extract of Phellinus sp. PL3 or Phellinsin A isolated from the same as an effective component for prevention and treatment of cardiac circuit disease | |
KR101181347B1 (en) | Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extracts of Dictamnus dasycarpus as active ingredient | |
US8404282B2 (en) | Compositions for suppressing obesity | |
KR20150124108A (en) | Food and pharmaceutical composition for preventing or improving obesity comprising Curcuma longa extract as effective component | |
KR102183916B1 (en) | Composition containing complex extracts for preventing, improving or treating dyslipidemia | |
KR102496752B1 (en) | Fruits of Acanthopanax Sessiliflorus extract including alcoholic liver injury prevention functional ingredients and method for manufacturing it | |
KR102183915B1 (en) | Composition containing complex extracts for improving blood circulation | |
KR102290222B1 (en) | Composition for preventing or treating nonalcoholic fatty liver disease comprising extract of Rubus coreanus | |
KR102355441B1 (en) | Composition containing extract of Angelica gigas, extract of Cynanchum wilfordii and extract of Ginko biloba leaves for improving blood circulation | |
KR101164908B1 (en) | The composition for the treatment of cancers or inhibition of metastasis containing the extracts or fractions of Asparagus cochinchinensis as active ingredient | |
KR101904819B1 (en) | Composition comprising Fermented Momordica charantia L. and Allium sativum L. using Amyloliquefaciens Bacillus Jis-1 for lowering blood glucose or preventing and treating diabetes mellitus | |
KR102242002B1 (en) | Composition for preventing or treating fatty liver disease comprising solid phase fermented red ginseng extract by cordyceps | |
KR101954890B1 (en) | A composition for treating or improving non-alcoholic fatty liver disease comprising Seahorse extract | |
KR101833332B1 (en) | n-Hexane fractions of Morning glory seeds for nephroprotection and treating acute renal failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |